Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.
US-based oncology therapy developer Nurix Therapeutics has filed to raise up to $100m in an initial public offering that would provide an exit for pharmaceutical producer Celgene.
Formerly known as Kura Therapeutics, Nurix is developing small molecule drugs intended to treat cancer and immune disorders by modulating levels of cellular protein. It was co-founded by John Kuriyan and Michael Rapé from University of California (UC), Berkeley, and Arthur Weiss, a professor at UC San Francisco.
Proceeds from the offering…
